Olink Holding AB (publ) (OLK) News

Olink Holding AB (publ) (OLK): $11.35

0.56 (+5.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter OLK News Items

OLK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OLK News Highlights

  • For OLK, its 30 day story count is now at 4.
  • Over the past 14 days, the trend for OLK's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • AB are the most mentioned tickers in articles about OLK.

Latest OLK News From Around the Web

Below are the latest news stories about Olink Holding AB (publ) that investors may wish to consider to help them evaluate OLK as an investment opportunity.

Leerink Partners Remains a Buy on Olink Holding (OLK)

Leerink Partners analyst Puneet Souda reiterated a Buy rating on Olink Holding (OLK – Research Report) yesterday and set a price target of $25.00. The company's shares closed last Tuesday at $18.60. According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of -3.5% and a 36.7% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on Olink Holding is a Moderate Buy with an average price target of $25.00.

Catie Powers on TipRanks | February 15, 2022

8 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital

In this article, we will be looking at the 8 medical stocks to buy according to Mitchell Blutt’s Consonance Capital. You can skip our detailed analysis of these stocks and head directly to 3 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital. Mitchell Blutt is an American physician-businessman. He is one of the […]

Yahoo | February 15, 2022

Olink reports fourth quarter and full year 2021 financial results and provides outlook for 2022

Uppsala, Sweden, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2021, and provided revenue guidance for the full year 2022. Highlights Fourth quarter revenue totaled $43.7 million, representing year over year growth of 61% on a reported basis and 45% on a constant currency adjusted like-for-like basisFull year 2021 revenue totaled $95.0 million, achieving yea

Yahoo | February 14, 2022

Olink to present at February investor conferences

UPPSALA, Sweden, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Jon Heimer, CEO, and Oskar Hjelm, CFO, will participate in the following virtual investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFireside chat on Tuesday, February 15th at 8:30 am ET 11th Annual SVB Leerink Global Healthcare ConferenceFireside chat on Friday, February 18th at 8:40 am ET BTIG hosted events are intended for prospecti

Yahoo | February 1, 2022

Nasdaq’s European Markets Delivered Record Year in 2021

- Solidified Nasdaq position as the leading European listings hub with 219 new equity listings, including a record number of 174 initial public offerings (IPOs), raising a total of EUR 13.4 billion- Retail inflow and large interest in SME trading spurred all-time high levels in equity and derivative trading- Continued to lead in ESG with venture investment in Puro.earth and new product launches STOCKHOLM, Sweden, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that Nasdaq

Yahoo | January 21, 2022

Sequanta selects Olink® Explore 3072 to analyze new cohort study in China

UPPSALA, Sweden, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based in China, will use Olink® Explore 3072 to analyze 1,000 patient samples from a new cohort study in China. Since 2021, Sequanta and Olink's partnership has provided Sequanta access to Olink’s Proximity Extension Assay (PEA) technology. This collaboration has enabled end-to-end multi-omic clinical studies, which could also

Yahoo | January 20, 2022

Olink Holding (OLK) Gets a Buy Rating from Leerink Partners

Leerink Partners analyst Puneet Souda maintained a Buy rating on Olink Holding (OLK – Research Report) yesterday. The company's shares closed last Tuesday at $14.27. According to TipRanks.com, Souda is a 3-star analyst with an average return of 1.6% and a 44.0% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on Olink Holding is a Moderate Buy with an average price target of $44.00.

Brian Anderson on TipRanks | January 11, 2022

Why Olink Holding Stock Blasted Higher Today

The company posted some impressive anticipated growth figures in a new set of preliminary results.

The Motley Fool | January 10, 2022

Olink announces preliminary unaudited revenue for the fourth quarter and full year 2021

UPPSALA, Sweden, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced preliminary unaudited revenue for the fourth quarter and year ended December 31, 2021, and additional select unaudited performance metrics. Revenues for the fourth quarter 2021 are expected to be between $43.2 million and $43.7 million, versus $27.2 million in the corresponding quarter of last year. Full year 2021 revenues are expected to be between $94.5 million and $95.0 million,

Yahoo | January 10, 2022

Olink to present at the 40th Annual J.P. Morgan Healthcare Conference

UPPSALA, Sweden, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced it will be virtually participating in the 40th Annual J.P. Morgan Healthcare Conference. Jon Heimer, CEO, is scheduled to present on Wednesday, January 12th, 2022, at 9:00 am ET. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at https://investors.olink.com/investor-relations. About OlinkOlink Holding AB (Nasdaq: OLK) i

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5893 seconds.